Skip to main content
SpringerLink
Log in

Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris

  • Angina Pectoris and Ischemic Heart Disease
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The antianginal effects of beta-adrenoceptor antagonists are achieved by a reduction in myocardial oxygen demand. This is a rational approach to treatment in patients whose angina is caused by a fixed stenosis. However, dynamic coronary vasospasm is an important factor in patients with chronic stable angina. Nifedipine increases myocardial oxygen supply by reducing coronary vascular tone and is a logical approach to treatment in these patients. For monotherapy of angina, nifedipine is less effective than the beta-adrenoceptor antagonists, but the combination has additive effects in reducing the frequency of anginal episodes and improving exercise tolerance.

Plasma concentrations of nifedipine are closely related to clinical efficacy, and the variable first-pass metabolism of the drug leads to wide interindividual differences in peak concentrations and duration of action. Increasing the size of individual doses of nifedipine carries a risk of enhanced side effects due to high peak plasma concentrations. Optimal treatment may be more appropriately achieved in some patients by a slow release formulation, but with an increased frequency of administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kostis JB, Lacy CR, Frishman WH. Use of beta blockers in the treatment of angina pectoris. In: KostisJB, DeFeliceEA, eds. Beta Blockers in the treatment of cardiovascular disease. Boston: Raven Press, 1985:94–120.

    Google Scholar 

  2. Alderman EL, Davies RO, Crowley JJ, Lopes MG, Brooker JZ, Friedman JP, Graham AG, Matlof HM, Harrison DC. Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation 1975;51:964–975.

    Google Scholar 

  3. Jackson G, Schwartz J, Kates RE, Winchester M, Harrison DC. Atenolol: Once-daily cardioselective beta blockade for angina pectoris. Circulation 1980;61:555–560.

    Google Scholar 

  4. Feigl EO, Buffington CW, Nathan HJ. Adrenergic coronary vasoconstriction during myocardial underperfusion. Circulation 1987;75(Suppl 1):1–5.

    Google Scholar 

  5. Rubio R, Berne RM. Regulation of coronary blood flow. Prog Cardiovasc Dis 1975;18:105–122.

    Google Scholar 

  6. Mudge GH Jr, Goldberg S, Gunther S, Mann T, Grossman W. Comparison of metabolic and vasoconstrictor stimuli on coronary vascular resistance in man. Circulation 1979; 59:544.

    Google Scholar 

  7. Feigl EO, Coronary physiology. Physiol Rev 1983;63:1.

    Google Scholar 

  8. Marcus ML. The coronary circulation in health and disease. New York: McGraw-Hill Book Company, 1983.

    Google Scholar 

  9. Vanhoutte PM, Rimele TJ. Role of endothelium in the control of vascular smooth muscle. J Physiol (Paris) 1982–1983;78:681–686.

    Google Scholar 

  10. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent vasodilator and nitrovasodilator-induced relaxation may be mediated through cyclic GMP formation and GMP-dependent protein phosphorylation. Nature 1983; 306:174–176.

    Google Scholar 

  11. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH. The nature of endothelium-derived vascular relaxant factor. Nature 1984;308:645–647.

    Google Scholar 

  12. Brown BG, Bolson EL, Dodge HT. Dynamic mechanisms in human coronary stenosis. Circulation 1984;70:917–922.

    Google Scholar 

  13. Maseri A, Chierchia S, L'Abbate A. Pathogenetic mechanisms underlying the clinical events associated with atherosclerotic heart disease. Circulation 1980;62(Suppl V):V3.

    Google Scholar 

  14. Maseri A. Active and quiescent phases in coronary disease: Role of varied and changing susceptibility to dynamic obstruction. International Lecture at the 55th Scientific Session of the American Heart Association Circulation. 1982; 11B.

  15. Freudenberg H, Lichtlen PR. The normal wall segment in coronary stenosis—a postmorten study. Z Kardiol 1981; 70:683.

    Google Scholar 

  16. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43–52.

    Google Scholar 

  17. Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog. Circ Res 1983;53:8.

    Google Scholar 

  18. Hamer J. Beta-adrenergic blocking drugs. In: HamerJ, ed. Drugs for heart disease. London: Chapman and Hall, 1979:148–243.

    Google Scholar 

  19. Winbury MM. Experimental studies on the mechanism of action on nitrates and beta-adrenergic blockers. In: BoissierJR, ChicheP, eds. Pharmacologic clinique des medicaments antiaryineaux. Paris: Sandoz 1974;153.

    Google Scholar 

  20. Guth BD, Tajimi T, Seitelberger R, Lee J-D, Matsuzaki M, Ross J Jr. Experimental exercise-induced ischemia: Drug therapy can eliminate regional dysfunction and oxygen supply-demand imbalance. J Am Coll Cardiol 1986;7:1036–1046.

    Google Scholar 

  21. Fleckenstein A, Tritthart H, Dmring HJ, Byon KS. BAY a 1040—ein hochaktiver Ca2+ antagonistischer inhibitor der elektro-mechanischen koppelungsprozesse im warmblutermyokard. Arzneim-Forsch 1972;22:22–33.

    Google Scholar 

  22. Backe RJ, Tockman BA. Effect of nitroglycerin and nifedipine on subendocardial perfusion in the presence of a flow limiting coronary stenosis in the awake dog. Circ Res 1982;50:678–687.

    Google Scholar 

  23. Theroux P, Taeymans Y, Waters DD. Calcium antagonists. Clinical use in the treatment of angina. Drugs 1983;25:178–195.

    Google Scholar 

  24. Sherman LG, Liang C-S. Nifedipine in chronic stable angina: A double-blind placebo-controlled cross-over trial. Am J Cardiol 1983;51:706–711.

    Google Scholar 

  25. Braun S, Terdiman R, Berenfield D, Laniado S. Clinical and hemodynamic effects of combined propranolol and nifedipine therapy versus propranolol alone in patients with angina pectoris. Am Heart J 1985;3:478–485.

    Google Scholar 

  26. Bassan M, Weiler-Ravell D, Shalev O. The additive antianginal action of oral nifedipine in patients receiving propranolol: Magnitude and duration of effect. Circulation 1982;66:710–716.

    Google Scholar 

  27. Findlay IN, MacLeod K, Ford M, Gillen G, Elliott AT, Dargie HJ. J Treatmetn of angina pectoris with nifedipine and atenolol: Efficacy and effect on cardiac function. Br Heart J 1986;55:240–245.

    Google Scholar 

  28. Daniel WG, Reil G-H, Schober O, Creutzig H, Lichtlen PR. Effects of combined nifedipine and propranolol treatment on regional myocardial blood flow in coronary patients. 6th International Adalat Symposium 1985;414–421.

  29. Lynch P, Dargie H, Krikler S, Krikler D. Objective assessment of antianginal treatment: A double-blind comparison of propranolol, nifedipine, and their combination. Br Med J 1980;281:184–187.

    Google Scholar 

  30. Kenmure AC, Scruton JH. A double-blind controlled trial of the antianginal efficacy of nifedipine compared with propranolol. Br J Clin Pract 1979;33:49–51.

    Google Scholar 

  31. Këyrilainen O, Bae E, Rytkönen U, Mathieson MS, Wendelin H. Meloprolol, nifedipine and the combination in effort angina pectoris. I Clinical effects (abstract No. 1464). Eur Heart J 1984;5(Suppl 1):293.

    Google Scholar 

  32. Uusitalo A, Arstila M, Bae EA, Harkonen R, Keyrilainen O, Rytkonen U, Schjelderup-MathiesenPM, WendelinH. Metoprolol, nifedipine, and the combination in stable effort angina pectoris. Am J Cardiol 1986;57:733–737.

    Google Scholar 

  33. Tweddel AC, Beattie JM, Murray RG, Hutton I. The combination of nifedipine had propranolol in the management of patients with angina pectoris. Br J Clin Pharmacol 1981; 12:229–233.

    Google Scholar 

  34. Jenkins RM, Nagle RE. The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris. Postgrad Med J 1982;58:697–700.

    Google Scholar 

  35. Ekelund LG, OroL. Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study. Clin Cardiol 1979;2:203–211.

    Google Scholar 

  36. Young KD, McDonald G. Treatment of angina pectoris in general practice with a combination of nifedipine and betablocker. Br J Clin Pract 1982;36:103–110.

    Google Scholar 

  37. De Buitleir M, Rowland E, Krikler DM. Combination of nifedipine with atenolol or propranolol in chronic stable angina (abstract No. 546). Eur Heart J 1984; (Suppl 1): 128.

  38. Challenor VF, Waller DG, George CF. The addition of sustained-release nifedipine to atenolol for chronic stable angina pectoris (abstract). Cardiovasc Drugs Ther 1987; 1(3):220.

    Google Scholar 

  39. Brugmann U, Blasini R, Rudolph W. Anti-ischemic effect of nifedipine in long-acting form: Results of a randomized, double-blind placebo-controlled acute cross-over study. Herz 1983;8(4):206–210.

    Google Scholar 

  40. Chaitman BR, Wagwiart P, Pasternac A, Brevers G, Scholl JM et al. Improved exercise tolerance after propranolol, diltiazem or nifedipine in angina pectoris. Comparison at 1, 3 and 8 hours and correlation with plasma drug concentration. Am J Cardiol 1984;53:1–9.

    Google Scholar 

  41. Stern Z, Zylber-Kartz E, Levy M. Nifedipine plasma concentration in patients treated for angina pectoris. Int J Clin Pharmacol Ther Toxicol 1984;22:198–203.

    Google Scholar 

  42. VanHarten J, Burggraaf K, Danhof M, Van Brummelen P, Breimber D. Negligible sublingual absorption of nifedipine. Lancet 1987;12(2):1363–1365.

    Google Scholar 

  43. Challenor VF, Waller DG, Gruchy BS, Renwick AG, George CF, McMurdo ET, McEwen J. The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine. Br J Clin Pharmacol 1986;22:565–570.

    Google Scholar 

  44. Zylber-Katz E, Koren G, Granit L, Levy M. Bioavailability of nifedipine. A comparison between two preparations. Biopharm Drug Dispos 1984;5:109–115.

    Google Scholar 

  45. Jariwalla AG, Anderson EG. Production of ischemic cardiac pain by nifedipine. Br Med J 1978;1:1181–1182.

    Google Scholar 

  46. Engel H-J, Lichtlen PR. Beneficial enhancement of coronary blood flow by nifedipine. Comparison with nitroglycerin and beta-blocking agents. Am J Med 1981;71:658–666.

    Google Scholar 

  47. O'Keefe JC, Creamer JE, Banin SO. Efficacy of nisoldipine combined with beta-adrenergic-blocking drugs in the treatment of chronic stable angina. Clin Cardiol 1987;10:345–350.

    Google Scholar 

  48. Johnston DL, Lesoway R, Humen DP, Kostuk WJ. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine nad diltiazem in exertional angina pectoris. A placebo-controlled, double-blind, randomized crossover study. Am J Cardiol 1985;55:680–687.

    Google Scholar 

  49. Winniford MD, Fulton KL, Corbett JR, Croft CH, Hillis LD. Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort. A randomized double-blind crossover study. Am J Cardiol 1985;55:281–285.

    Google Scholar 

  50. Krikler DM. Calcium antagonists for chronic stable angina pectoris. Am J Cardiol 1987;59:95B-100B.

    Google Scholar 

  51. Henry PD. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazen. Am J Cardiol 1980;46:1047–1058.

    Google Scholar 

  52. Anastassiades CJ. Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J 1982;284:506.

    Google Scholar 

  53. Opie LH, White DA. Adverse interaction between nifedipine and beta-blockade. Br Med J 1980;281:1462.

    Google Scholar 

  54. Findlay IN, Dargie HJ. The effects of nifedipine, atenolol and that combination on left ventricular function. Postgrad Med J 1983;59(Suppl 2):70–73.

    Google Scholar 

  55. Joshi PI, Dalal JJ, Ruttley MSJ, Sheridan DJ, Henderson AH. Nifedipine and left ventricular function in beta-blocked patients. Br Heart J 1981;45:457.

    Google Scholar 

  56. Winniford MD, Markham RV Jr, Firth BG, Nicod P, Hillis LD. Hemodynamic and electrophysiological effects of verapamil and nifedipine in patients on propranolol. Am J Cardiol 1982;50:704–710.

    Google Scholar 

  57. Rowland E, Razis P, Sugrue D, Krikler RD, Acute and chronic hemodynamic and electrophysiological effects of nifedipine in patients receiving atenolol. Br Heart J 1983;50:383–389.

    Google Scholar 

  58. Packer M, Mellor J, Medina N Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG, Gorlin R. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982; 65:660.

    Google Scholar 

  59. Strauss WE, Parisis AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985;71:951.

    Google Scholar 

  60. Kostuk WJ, Pflugfelder P. Comparative effects of calcium entry-blocking drugs, beta-blocking drugs and their combination in patients with chronic stable angina. Circulation 1987;75 (Suppl V):114–121.

    Google Scholar 

  61. Krikler D, Rowland E. Effect of nifedipine as compared with verapamil on atrioventricular conduction. 4th International Adalat Symposium 1980:241–244.

  62. Covinsky JO, Hamburger SC. Slow channel blockers. South Med J 1983;76:55–64.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology, Southampton General Hospital, Southampton, UK

    Vivian F. Challenor, Derek G. Waller & Charles F. George

Authors
  1. Vivian F. Challenor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derek G. Waller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles F. George
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Challenor, V.F., Waller, D.G. & George, C.F. Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris. Cardiovasc Drug Ther 3 (Suppl 1), 275–285 (1989). https://doi.org/10.1007/BF00148472

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00148472

Key Words

Search

Navigation